AstraZeneca (LSE:AZN) reports positive late-stage results for TAGRISSO plus savolitinib in the SAFFRON Phase III trial in difficult-to-treat NSCLC. ENHERTU meets key goals in the DESTINY-Lung04 Phase III trial with survival benefits in NSCLC patient groups with limited options. The company discontinues development of lung cancer candidate volrustomig after trial results show a lack of efficacy. These moves highlight how fast lung cancer treatment and related technologies are changing, so it...

AstraZeneca stock is down over the year to date but has still returned 53.6% over the past 5 years, while the latest valuation work suggests the current share price may sit well below an intrinsic value estimate. Both the Discounted Cash Flow (DCF) model and the market multiple checks indicate AstraZeneca appears undervalued at recent levels. A 53.6% gain over 5 years indicates AstraZeneca has already created substantial shareholder value, so any current discount matters for long term...

AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.

European equities traded in the US as American depositary receipts were trending lower in late Tuesd

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the...

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

Positive results elsewhere helped investors look past another pipeline failure.

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

Find insights on Sandoz’s deal with Henlius, AstraZeneca and more in the latest Market Talks covering the health care sector.

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in...

A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trail, but the company said other Phase 3 volrustomig trials would continue as planned.

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing the first approved CELMoD therapy in this disease setting. See our latest analysis for Bristol-Myers Squibb. The ZENBEXUS approval lands at a time when Bristol-Myers Squibb’s momentum has picked up, with the share price at US$64.65 and a 30 day share price return of 13.52%. That builds on a 20.93% year to date share price return and a...